PDCD1 and neoplasm: Circulating CD4+ T-cell levels showed a peak and subsequent decline during the combination therapy but continued to increase in subsequent therapy cycles; this may be associated with tumour remission, which is consistent with the challenged tumour shrinkage 10 weeks after cryotherapy, as described in another article (36), and may also be a PD-1 trailing effect (37).